Research programme: Protein biosynthesis inhibitors - Anima Biotech/Eli Lilly and Company
Latest Information Update: 10 Jul 2025
At a glance
- Originator Anima Biotech; Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Protein biosynthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 10 Jul 2025 Early research in Undefined indication is ongoing in USA (unspecified route) (Anima Biotech pipeline, July 2025)
- 28 Dec 2024 No recent reports of development identified for research development in Unspecified in USA
- 02 Dec 2022 Early research is ongoing in USA (Anima Biotech pipeline, December 2022)